Journal article
Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution
Brachytherapy, v 21(1), pp 79-84
Jan 2022
PMID: 34756821
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
To evaluate our institutional outcomes utilizing Cs-131 prostate brachytherapy (PB) for the intermediate-risk (IR) group of prostate cancer patients.
We reviewed a prospectively collected database of men treated with Cs-131 PB between 2006 and 2019. Patients with less than 24-months follow-up were excluded. Patients were classified as IR if they had one of the following factors: Gleason Score 7, prostate specific antigen >10 but <20 ng/mL, or T2b-c on clinical exam. We defined unfavorable-IR (UIR) as having either Grade Group 3, >1 IR factors, or ≥50% positive core biopsies. The Kaplan-Meier method was used to estimate actuarial event-time probabilities for biochemical freedom from disease (BFD).
A total of 335 patients with a median follow-up of 70.1 months (IQR 48.3–106.3 months) were identified. Androgen deprivation therapy (ADT) was used in 7.2% of patients. Favorable-IR (FIR) patients were commonly treated with PB alone (91.8%). FIR patients who underwent PB alone had a 5-year BFD of 98.1%. UIR patients were commonly treated with external beam radiotherapy plus PB (61.2%). These patients had 5-year BFD of 91.1%. The 5-year BFD for UIR patients treated without ADT was 90.9%, whereas it was 95.0% among UIR patients treated with ADT (log-rank p = 0.83).
FIR patients have excellent outcomes when treated with PB alone. External beam radiotherapy plus PB is a reasonable treatment approach for UIR patients. Future studies may elucidate which IR patients would benefit from treatment intensification.
Metrics
Details
- Title
- Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution
- Creators
- Joshua L. Rodríguez-López - University of Pittsburgh School of MedicineAnkur K. Patel - UPMC Hillman Cancer CenterRonald M. Benoit - University of Pittsburgh School of MedicineSushil Beriwal - UPMC Hillman Cancer CenterRyan P. Smith - UPMC Hillman Cancer Center
- Publication Details
- Brachytherapy, v 21(1), pp 79-84
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000768792300011
- Scopus ID
- 2-s2.0-85119202167
- Other Identifier
- 991021897284104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging